Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection (RiCOTTA)

Rifampicin Combination Therapy Versus Targeted Antimicrobial Monotherapy in the Oral Antimicrobial Treatment Phase of Staphylococcal Prosthetic Joint Infection

In this Dutch multicenter clinical trial, patients with a staphylococcal prosthetic joint infection, will, in the oral antibiotic treatment phase, be randomized between clindamycin monotherapy and rifampicin / levofloxacin combination therapy. The clinical endpoint will be treatment success one year after finishing antimicrobial treatment.

Study Overview

• Status: Recruiting
• Conditions: Prosthetic-joint Infection; Infection Hip; Infection; Knee, Joint
• Intervention / Treatment: Drug: Rifampicin and levofloxacin; Drug: Clindamycin

Detailed Description

This is a pragmatic, multicenter, randomized controlled open label trial with a non-inferiority design, comparing the efficacy of rifampicin-based combination antimicrobial therapy versus antimicrobial monotherapy with clindamycin during the oral treatment phase of prosthetic joint infection caused by Staphylococcus spp. The total duration of follow-up will be 15 months from the initial DAIR.

All adult patients, aged 18 years or older, diagnosed and hospitalized with hip- or knee PJI caused by Staphylococcus spp and treated by the DAIR strategy (see Interventions), are eligible for inclusion. The diagnosis of PJI is defined according to the EBJIS 2021 criteria. Exclusion criteria are a contra-indication for rifampicin (due to a resistant strain, a proven allergic reaction, difficult drug-drug-interactions or other contra-indications as listed in the SmPC's of the antibiotics), a contra-indication for levofloxacin and clindamycin and cotrimoxazole and tetracyclines (due to a resistant strain, a proven allergic reaction, difficult drug-drug-interactions or other contra-indications as listed in the SmPC's of the antibiotics), (iii)complicated S. aureus bacteremia or concurrent endocarditis requiring long-term iv antibiotic treatment > 3 weeks , (iv) an infection for which there are no suitable antibiotic choices to permit randomization between the two arms of the trial (for instance, where organisms are only sensitive to intravenous antibiotics), (v) treatment failure before the start of oral therapy, (vi) more than two separate surgical debridements , (vii)an unsatisfactory response to initial treatment leading to continuation of intravenous therapy beyond day 21, (viii) patients with an expected life expectancy <12 months, (ix) patients with a tumor prosthesis , (x) patients receiving chemotherapy for active malignancy in the next 12 months, (xi) patients who are scheduled in advance for chronic suppressive antibiotic therapy after the initial 12 weeks of antibiotic treatment, (xii) The patient is unlikely to comply with trial requirements following randomization in the opinion of the investigator, (xiii) Pregnancy or breastfeeding, (xiv) Patients who are not able to read or communicate in Dutch or English will be excluded from participating in this study.

The main trial endpoint is treatment success 15 months after DAIR (=1 year after finishing antibiotic treatment). Treatment success will be defined as absence of all of the following:

(I) Infection related re-surgery of the initially affected prosthetic joint (II) New antibiotic treatment for suspected or proven infection of the index joint.

(III) Ongoing use of antibiotics for the index joint at the end of follow-up. (IV) Death

Secondary outcomes are (a) Quality of life, measured with the 5-level EQ-5D version (EQ-5D-5L) questionnaires. The EQ-5D-5L is a standardized and validated measure of health status developed by the EuroQol Group to provide a comprehensive generic measure of health for clinical and economic appraisal. This 'quality of life' questionnaire will be scored at the time of randomization, at week 6 after the initial surgical debridement and after 3 months.

(b) Adverse events. The number of SAEs during antimicrobial treatment and follow up ii. The number of switches to a different oral regimen, iii. The number of antibiotic associated AEs (classified by the modified Hartwig and Siegel scale). (c) The number of patients developing Clostridioides difficile infection during treatment. (d) The occurrence of rifampicin resistance in bacteria in patients with a microbiologically confirmed failure of treatment.

• Study Type: Interventional
• Enrollment (Estimated): 316
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Henk Scheper, MD; Phone Number: 071-5299239; Email: h.scheper@lumc.nl
• Study Contact Backup: Name: Mark De Boer, MD PhD; Phone Number: 071-5269111; Email: M.G.J.de_Boer@lumc.nl

Study Locations

• Netherlands
  • Amsterdam, Netherlands
    • Recruiting
    • Amsterdam UMC
    • Contact: Edgar Peters
  • Amsterdam, Netherlands
    • Recruiting
    • OLVG
    • Contact: Rudolf Poolman
  • Groningen, Netherlands
    • Recruiting
    • UMCG
    • Contact: Marjan Wouthuyzen-Bakker
  • Groningen, Netherlands
    • Not yet recruiting
    • Martini Ziekenhuis
    • Contact: Bas ten Have
  • Hoofddorp, Netherlands
    • Recruiting
    • Spaarne Gasthuis
    • Contact: Peter Nolte
  • Leeuwarden, Netherlands
    • Recruiting
    • Medisch Centrum Leeuwarden
    • Contact: Wierd Zijlstra
  • Leiderdorp, Netherlands
    • Recruiting
    • Alrijne Ziekenhuis
    • Contact: Rachid Mahdad
  • Nijmegen, Netherlands
    • Recruiting
    • Radboud UMC
    • Contact: Wim Rijnen
  • Nijmegen, Netherlands
    • Recruiting
    • Sint Maartenskliniek
    • Contact: Karn Veerman
  • Rotterdam, Netherlands
    • Not yet recruiting
    • Erasmus MC
    • Contact: Koen Bos
  • Tilburg, Netherlands
    • Recruiting
    • Elisabeth Tweesteden Ziekenhus
    • Contact: Olav van der Jagt
  • Zwolle, Netherlands
    • Recruiting
    • Stichting Isala Klinieken
    • Contact: Jolanda Lammers
  • Zuid Hollans
    • Leiden, Zuid Hollans, Netherlands, 2333ZA
      • Recruiting
      • LUMC
      • Contact: Henk Scheper, MD PhD; Phone Number: 0644544573; Email: h.scheper@lumc.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• >18 years of age
• Confirmed staphylococcal prosthetic hip or knee joint infection according to the current EBJIS 2021 definition of PJI
• The causative agents are (or include) S. aureus or and/or Coagulase-negative staphylococci (CNS)
• Treatment is according to the DAIR-procedure

Exclusion Criteria:

(i) a contra-indication for rifampicin (e.g. a resistant strain or proven allergic reaction or difficult drug-drug-interactions) (ii) complicated S. aureus bacteremia or concurrent endocarditis requiring long-term iv antibiotic treatment > 2 weeks (iii) An infection for which there are no suitable antibiotic choices to permit Randomization between the two arms of the trial (for instance, where organisms are only sensitive to intravenous antibiotics) (iv) treatment failure before the start of oral therapy, (v) an unsatisfactory response to initial treatment leading to continuation of intravenous therapy beyond day 21, (vi) patients with an expected life expectancy <12 months, (vii) patients with a tumor prosthesis (viii) patients receiving chemotherapy for active malignancy in the next 12 months (ix) patients who are scheduled in advance for chronic suppressive antibiotic therapy for >12 months, (x) The patient is unlikely to comply with trial requirements following Randomization in the opinion of the investigator (xi) Pregnancy (xii) Patients who are not able to read or communicate in Dutch or English will be excluded from participating in this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Oral rifampicin-based combination therapy; rifampicin 450mg BID + levofloxacin 500mg BID in the oral treatment phase with a total duration of antibiotics of 12 weeks	Drug: Rifampicin and levofloxacin; antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Experimental: Oral monotherapy with clindamycin; clindamycin 600mg TID in the oral treatment phase with a total duration of antibiotics of 12 weeks	Drug: Clindamycin; antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
treatment success	Proportion of patients with treatment success 15 months after DAIR (=1 year after finishing antibiotic) in both randomised groups treatment). Treatment success will be defined as absence of all of the following: (I) Infection related re-surgery of the initially affected prosthetic joint (II) New antibiotic treatment for suspected or proven infection of the index joint. (III) Ongoing use of antibiotics for the index joint at the end of follow-up. (IV) Death	15 months after DAIR

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life of patients at baseline and after 6 and 12 weeks	Quality of life, measured with the 5-level EQ-5D version (EQ-5D-5L) questionnaires. The number and percentage of patients reporting each level of problem on each dimension of the EQ-5D-5L will be decribed.	at the time of randomization, at week 6 after surgical debridement and after 3 months.
Adverse events	The number of (S)AEs during antimicrobial treatment and follow up (including mortality). ii. The proportion of patients switching to a different oral regimen in both study arms iii. The proportion of patient with antibiotic side effects (classified by the modified Hartwig and Siegel scale) in both study arms iv. The proportion of patient developing Clostridioides difficile infection during treatment in both study arms v. The proportion of patient with rifampicin resistance in bacteria in patients with a microbiologically confirmed failure of treatment in both study arms.	through study completion, an average of 15 months
Development of new rifampicin resistance	The proportion of patients developing rifampicin resistance in patients with a confirmed microbiological relapse with the same micro-organism in both study arms	through study completion, an average of 15 months

Collaborators and Investigators

• Sponsor: Leiden University Medical Center
• Collaborators: Radboud University Medical Center; University Medical Center Groningen; Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Reinier Haga Orthopedisch Centrum; Medical Centre Leeuwarden; Sint Maartenskliniek; Elisabeth-TweeSteden Ziekenhuis; Rijnstate Hospital; Onze Lieve Vrouwe Gasthuis; Spaarne Gasthuis; Isala; Martini Hospital Groningen; Alrijne Hospital; Tergooi Hospital
• Investigators: Study Director: Henk Scheper, MD, LUMC

Publications and helpful links

General Publications

• Scheper H, Gerritsen LM, Pijls BG, Van Asten SA, Visser LG, De Boer MGJ. Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2021 Jul 1;8(7):ofab298. doi: 10.1093/ofid/ofab298. eCollection 2021 Jul.

Helpful Links

• Website with information for patients and physicians about RiCOTTA study

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2023
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: November 23, 2023
• First Submitted That Met QC Criteria: December 6, 2023
• First Posted (Estimated): December 15, 2023

Study Record Updates

• Last Update Posted (Estimated): December 15, 2023
• Last Update Submitted That Met QC Criteria: December 6, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: levofloxacin; clindamycin; prosthetic joint infection; rifampicin; antimicrobial treatment
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Joint Diseases; Musculoskeletal Diseases; Arthritis; Infections; Communicable Diseases; Arthritis, Infectious; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Leprostatic Agents; Protein Synthesis Inhibitors; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP3A Inducers; Antitubercular Agents; Antibiotics, Antitubercular; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP1A2 Inhibitors; Anti-Infective Agents, Urinary; Rifampin; Clindamycin; Clindamycin palmitate; Clindamycin phosphate; Levofloxacin
• Other Study ID Numbers: 2022-501620-26-00

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No